Pulmonx Corp
For the period ended Jun 30, 2024. Filed Aug 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 2, 2024
LUNG$2.800.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Deficit | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances at January 1, 2024 | 38,516,383 | $39 | $526,797 | $2,640 | $(411,161) | $118,315 |
| Issuance of common stock upon vesting of restricted stock units | 177,610 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | 28,116 | — | 57 | — | — | 57 |
| Issuance of shares pursuant to employee stock purchase plan | 90,066 | — | 808 | — | — | 808 |
| Stock-based compensation expense | — | — | 5,744 | — | — | 5,744 |
| Currency translation adjustment | — | — | — | (549) | — | (549) |
| Change in unrealized losses on marketable securities | — | — | — | (128) | — | (128) |
| Net loss | — | — | — | — | (13,749) | (13,749) |
| Balances at March 31, 2024 | 38,812,175 | 39 | 533,406 | 1,963 | (424,910) | 110,498 |
| Issuance of common stock upon vesting of restricted stock units | 328,336 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | 11,350 | — | 22 | — | — | 22 |
| Stock-based compensation expense | — | — | 5,980 | — | — | 5,980 |
| Currency translation adjustment | — | — | — | 40 | — | 40 |
| Change in unrealized losses on marketable securities | — | — | — | (30) | — | (30) |
| Net loss | — | — | — | — | (15,326) | (15,326) |
| Balances at June 30, 2024 | 39,151,861 | $39 | $539,408 | $1,973 | $(440,236) | $101,184 |
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Deficit | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances at January 1, 2023 | 37,555,565 | $38 | $502,712 | $1,575 | $(350,318) | $154,007 |
| Issuance of common stock upon vesting of restricted stock units | 66,895 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | 23,006 | — | 46 | — | — | 46 |
| Issuance of shares pursuant to employee stock purchase plan | 85,210 | — | 676 | — | — | 676 |
| Change in shares subject to repurchase | — | — | 56 | — | — | 56 |
| Stock-based compensation expense | — | — | 4,764 | — | — | 4,764 |
| Currency translation adjustment | — | — | — | 72 | — | 72 |
| Change in unrealized gains on marketable securities | — | — | — | 173 | — | 173 |
| Net loss | — | — | — | — | (15,860) | (15,860) |
| Balances at March 31, 2023 | 37,730,676 | 38 | 508,254 | 1,820 | (366,178) | 143,934 |
| Issuance of common stock upon vesting of restricted stock units | 222,598 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | 63,503 | — | 139 | — | — | 139 |
| Change in shares subject to repurchase | — | — | 47 | — | — | 47 |
| Repurchase of early exercised common stock options | (106) | — | — | — | — | — |
| Stock-based compensation expense | — | — | 5,891 | — | — | 5,891 |
| Currency translation adjustment | — | — | — | 170 | — | 170 |
| Change in unrealized losses on marketable securities | — | — | — | (34) | — | (34) |
| Net loss | — | — | — | — | (16,195) | (16,195) |
| Balances at June 30, 2023 | 38,016,671 | $38 | $514,331 | $1,956 | $(382,373) | $133,952 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.